The pharmaceutical sector has underperformed the broader market for the last 6-8 months. However, there is a case for reversal.
Within the pharma sector, Aurobindo Pharma looks interesting giving the valuation discount to its peers. Its strong pipeline in the injectables and biosimilars could be a significant opportunity for the company.
The vaccine opportunity is also getting traction. The COVID-19 vaccine presents a multi-year opportunity for the company.
API opportunities for the company have also strengthened post approval of the production linked incentive (PLI) scheme.
In the special segment ‘Moneycontrol Pro Ideas For Profit’, moneycontrol.com’s Anubhav Sahu gets details on how the stock is expected to perform going forward.
Watch the video for more.Disclaimer:
The views and investment tips expressed by investment experts are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.